ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,513 | -82.0% | 3,863 | -67.8% | 0.00% | -75.0% |
| Q2 2023 | $114,274 | +393948.3% | 11,991 | +357.0% | 0.00% | +300.0% |
| Q1 2023 | $29 | -77.9% | 2,624 | -70.4% | 0.00% | -80.0% |
| Q4 2022 | $131 | -99.8% | 8,865 | +213.3% | 0.01% | +400.0% |
| Q3 2022 | $54,000 | -78.7% | 2,830 | -76.2% | 0.00% | -83.3% |
| Q2 2022 | $253,000 | +1481.2% | 11,877 | +1282.7% | 0.01% | – |
| Q1 2022 | $16,000 | -57.9% | 859 | -52.3% | 0.00% | -100.0% |
| Q4 2021 | $38,000 | +65.2% | 1,799 | +80.6% | 0.00% | 0.0% |
| Q3 2021 | $23,000 | -70.5% | 996 | -65.1% | 0.00% | -50.0% |
| Q2 2021 | $78,000 | +116.7% | 2,856 | +132.4% | 0.00% | +100.0% |
| Q1 2021 | $36,000 | +227.3% | 1,229 | +223.4% | 0.00% | – |
| Q4 2020 | $11,000 | -96.7% | 380 | -96.6% | 0.00% | -100.0% |
| Q3 2020 | $332,000 | +591.7% | 11,340 | +615.9% | 0.00% | +100.0% |
| Q2 2020 | $48,000 | +26.3% | 1,584 | +25.5% | 0.00% | 0.0% |
| Q1 2020 | $38,000 | – | 1,262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
| Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
| Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
| Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
| MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
| 1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
| SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
| EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |